E
REGN icon

Ergoteles’s Regeneron Pharmaceuticals REGN Stock Holding History

Ergoteles’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,869
Closed -$1.34M – 661
2023
Q2 		$1.34M Buy
+1,869
New +$1.44M 0.06% 373
2023
Q1 		– Sell
-10,962
Closed -$7.91M – 1682
2022
Q4 		$7.91M Buy
+10,962
New +$8.09M 0.29% 82
2022
Q3 		– Sell
-2,222
Closed -$1.31M – 1912
2022
Q2 		$1.31M Buy
+2,222
New +$1.44M 0.04% 434
2021
Q3 		– Sell
-15,775
Closed -$8.81M – 1593
2021
Q2 		$8.81M Buy
+15,775
New +$7.99M 0.2% 147

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ergoteles's REGN Position: Q3 2023 in Review

Ergoteles sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 1,869 shares — an estimated $1.34M sold.

Ergoteles first reported a position in REGN in Q2 2021 and held it in 4 quarters. The position peaked at $8.81M in Q2 2021. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Ergoteles reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 1,869 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $1.34M.
  • Ergoteles first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Ergoteles's Regeneron Pharmaceuticals position peaked at $8.81M in Q2 2021.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.